Mol Ther Adv. 2026 Oct 17;34(4):201871. doi: 10.1016/j.omta.2026.201871. eCollection 2026 Dec 10.
ABSTRACT
GENE TARGET is a previously published framework designed to quantitatively assess the suitability of a specific monogenic neurodevelopment disorder (NDD) for development of genetic therapies, addressing the need for a systematic and rigorous approach to research prioritization and resource allocation. Here, to keep pace with the rapidly evolving knowledgebase, we refined the framework with more nuanced scoring definitions and added a resource guide to standardize evaluation of each criterion. Interrater agreement was assessed and found to be substantial for most domain/criteria scores among experienced users, primarily genetic counselors with at least two years of experience in translational genomic medicine. Secondary scoring adjudication by experts with clinical/molecular genetics and preclinical modeling expertise is recommended. Cross-disorder analysis of 57 NDD gene-disorder pairs evaluated at the Translational Neuroscience Center was performed, which identified clinical considerations, including establishing endpoints, as the most common translational research gap. Common barriers across disorders also included generating natural history data, establishing an early diagnosis, understanding dosage sensitivity, and demonstrating phenotypic reversibility. We further discuss application of this framework for gene editing and small molecules approaches. Future goals include the validation of GENE TARGET beyond academic research settings and the use of artificial intelligence to aid in preliminary scoring.
PMID:43034642 | PMC:PMC13769315 | DOI:10.1016/j.omta.2026.201871